What is Exelixis's common stock, shares, outstanding?

Exelixis (EXEL) reported common stock, shares, outstanding of $253.7M in Q1 2026.

How has Exelixis's common stock, shares, outstanding changed year-over-year?

Exelixis's common stock, shares, outstanding decreased by 7.8% year-over-year, from $275.03M to $253.7M.

What is the long-term trend for Exelixis's common stock, shares, outstanding?

Over 5 years (2020 to 2025), Exelixis's common stock, shares, outstanding has grown at a -3.4% compound annual growth rate (CAGR), from $311.63M to $262.48M.

Exelixis EXEL Common Stock, Shares, Outstanding

Common Stock, Shares, Outstanding at other companies

Summit TherapeuticsSMMT

——

IncyteINCY

——

Ionis PharmaceuticalsIONS

——

BridgeBio PharmaBBIO

——

Neurocrine BiosciencesNBIX

——

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$610.8M+10.0%

Gross profit$590.9M+10.2%

Operating income$251.3M+34.5%

Net income$210.5M+31.9%

EPS (diluted)$0.79+43.6%

Balance sheet

See full

Cash & equivalents$226.2M+23.1%

Total debt$169.5M-9.4%

Total equity$1.9B-9.2%

Total assets$2.6B-8.6%

Cash flow

See full

Operating cash flow$251.8M+19.1%

CapEx$1.5M-48.9%

Free cash flow$250.3M+20.1%

Valuation

See full

Market cap$13.05B+10.1%

Enterprise value$12.99B+9.5%

P/E15.7×-2.8×

P/S5.5×+0.3×

Profitability

See full

Gross margin96.4%-0.3pp

Operating margin39.4%+6.3pp

Net margin35.1%+7.1pp

FCF margin38.6%+2.9pp

Returns & leverage

See full

Return on equity41%+10.8pp

Debt / equity0.1×0.0×

Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesOutstanding.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's common stock, shares, outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Exelixis's common stock, shares, outstanding?: Exelixis (EXEL) reported common stock, shares, outstanding of $253.7M in Q1 2026.
How has Exelixis's common stock, shares, outstanding changed year-over-year?: Exelixis's common stock, shares, outstanding decreased by 7.8% year-over-year, from $275.03M to $253.7M.
What is the long-term trend for Exelixis's common stock, shares, outstanding?: Over 5 years (2020 to 2025), Exelixis's common stock, shares, outstanding has grown at a -3.4% compound annual growth rate (CAGR), from $311.63M to $262.48M.